Bokf Na Has $642,000 Stock Holdings in McKesson Co. (NYSE:MCK)

Bokf Na lessened its holdings in McKesson Co. (NYSE:MCK) by 11.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,099 shares of the company’s stock after selling 137 shares during the quarter. Bokf Na’s holdings in McKesson were worth $642,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of McKesson by 1.1% in the 1st quarter. JPMorgan Chase & Co. now owns 4,362,837 shares of the company’s stock valued at $2,342,190,000 after acquiring an additional 46,659 shares during the last quarter. Norges Bank bought a new position in shares of McKesson in the 4th quarter valued at $1,024,140,000. Putnam Investments LLC lifted its stake in shares of McKesson by 3.2% in the 4th quarter. Putnam Investments LLC now owns 1,997,963 shares of the company’s stock valued at $925,017,000 after acquiring an additional 62,242 shares during the last quarter. Swedbank AB bought a new position in shares of McKesson in the 1st quarter valued at $669,326,000. Finally, Boston Partners raised its position in McKesson by 4.1% during the 1st quarter. Boston Partners now owns 1,183,829 shares of the company’s stock worth $635,763,000 after purchasing an additional 47,140 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Performance

Shares of NYSE:MCK opened at $518.81 on Monday. McKesson Co. has a 52-week low of $417.65 and a 52-week high of $637.51. The firm has a fifty day moving average of $567.33 and a 200 day moving average of $557.76. The firm has a market capitalization of $67.28 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 1.18 and a beta of 0.44.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 7th. The company reported $7.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.21 by $0.67. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The company had revenue of $79.28 billion during the quarter, compared to analyst estimates of $82.53 billion. During the same period in the previous year, the business earned $7.27 earnings per share. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, sell-side analysts forecast that McKesson Co. will post 32.11 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 0.55%. This is a positive change from McKesson’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, August 30th. McKesson’s dividend payout ratio is presently 12.69%.

Insider Buying and Selling at McKesson

In other McKesson news, CEO Brian S. Tyler sold 3,753 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $626.03, for a total transaction of $2,349,490.59. Following the completion of the sale, the chief executive officer now directly owns 82,339 shares in the company, valued at $51,546,684.17. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 11,259 shares of company stock worth $6,635,492 over the last three months. Company insiders own 0.11% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on MCK. JPMorgan Chase & Co. raised their target price on McKesson from $656.00 to $661.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 9th. Robert W. Baird cut their price target on McKesson from $694.00 to $671.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Wells Fargo & Company cut their price target on McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Evercore ISI dropped their target price on shares of McKesson from $660.00 to $630.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and an average target price of $620.93.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.